Probiotics in the add-on treatment of otitis media in clinical practice
- Autori: Gelardi M.; La Mantia I.; Drago L.; Meroni G.; Aragona S.E.; Cupido G.; Vicini C.; Berardi C.; Ciprandi G.; Albanese G.; Anni A.; Antoniacomi G.; Artoni S.; Asprella G.; Azzaro R.; Azzolin A.; Balduzzi A.; Barbarino I.; Berardi C.; Bertetto B.I.; Bianchi A.; Bianco N.; Bonanno A.; Bordonaro C.; Brindisi A.M.; Bucolo S.; Bulzomi A.G.; Caligo G.; Capaccio P.; Capelli M.; Capone A.; Carboni S.; Carluccio G.; Casaula M.; Cassano M.; Cavaliere M.; Ciabattoni A.; Conti A.; Cordier A.; Cortellessa F.; Costanzo M.; Cupido F.; D'ascanio L.; Danza C.; D'auria C.; De Ciccio M.; De Luca C.; D'emila M.; Dessi R.; Di Lullo A.; D'urso M.; Falcetti S.; Falciglia R.; Fera G.; Ferrari G.; Ferraro S.M.; Fini O.; Fiorella M.; Floriddia A.; Asprea F.; Fusco C.; Fuson R.; Gallo A.; Gambardella T.; Gambardella G.; Giangregorio F.; Gramellini G.; Ierace M.; Ingria F.; La Paglia A.; Lanza L.; Lauletta R.; Lavazza P.; Leone M.; Lovotti P.; Luperto P.; Maniscalco F.; Marincolo I.; Martone R.; Melis A.; Messina A.; Milone V.; Mirra N.; Montanaro S.C.; Muia F.; Nacci A.; Nardello E.; Paderno L.; Padovani D.; Palma A.; Paoletti M.; Pedrotti I.; Petrillo F.; Piccolo M.; Pinto P.; Policarpo M.; Raguso M.; Ranieri A.; Romano G.; Rondinelli M.; Russo C.; Di Santillo L.S.; Sequino G.; Serraino E.M.; Spahiu I.; Spano G.; Stabile C.; Stagni G.; Stellin M.; Tassi S.; Tomacelli G.; Tombolini A.; Valenzise V.; Zirone A.
- Anno di pubblicazione: 2020
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/626265
Abstract
Otitis media (OM) affects the middle ear and is typically characterized by earache. OM may be classified as acute (AOM) or chronic (COM), based on symptom duration. OM may be clinically suspected, but the diagnosis is usually confirmed by the otoscopy. Antibiotic therapy is frequently used in clinical practice. However, antibiotics often induce intestinal and respiratory dysbiosis associated with some clinical problems. A one-month course of a probiotic mixture (Abincol® containing Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 million living cells), and Lactobacillus delbrueckii LDD01 (200 million living cells), was prescribed in the Group A, and was compared with no add-on treatment, such as the Group B. Patients were evaluated at baseline (T0), at the end of antibiotic treatment (T1), at the end of probiotic course (T2), and at the end of 3-month follow-up (T3).